4DMedical’s Qscan Partnership Signals Growing Market Footprint but Raises Adoption Questions

A Milestone in Australian Respiratory Imaging

4DMedical Limited (ASX:4DX), a leader in respiratory imaging technology, has announced a significant commercial agreement with Qscan Radiology Clinics, a prominent diagnostic imaging provider in Queensland. This deal follows a successful pilot program and represents 4DMedical's first Australian contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites, including the flagship CT LVAS™ technology.

Qscan operates 40 clinics across multiple Australian states, including Queensland, New South Wales, ACT, Tasmania, and Western Australia, making it a key player in the country’s medical imaging landscape. The partnership will see Qscan integrate 4DMedical’s advanced respiratory imaging solutions at select Brisbane practices, enhancing diagnostic capabilities for clinicians and patients alike.

Innovative Technology Meets Clinical Demand

The agreement covers several of 4DMedical’s proprietary products: CT LVAS™, Lung Density Analysis™ - Inspiration (LDAi), Functional Lung Density Analysis™ (LDAf), and Lung Texture Analysis™ (LTA). These tools provide clinicians with detailed, actionable insights into lung health, enabling earlier and more precise diagnoses of respiratory diseases.

4DMedical’s patented XV Technology® underpins these offerings, dynamically quantifying lung ventilation as patients breathe. This technology, cleared by the FDA, is designed to detect and monitor regional airflow abnormalities with unprecedented sensitivity, a critical advancement in respiratory care.

Strategic Growth and Market Expansion

The commercial contract with Qscan is billed on a Software-as-a-Service (SaaS) model, consistent with 4DMedical’s existing commercial partnerships. This approach facilitates seamless integration into hospital infrastructure and supports scalable revenue streams.

Andreas Fouras, Managing Director and CEO of 4DMedical, expressed enthusiasm about the partnership, highlighting its role in expanding access to cutting-edge lung health diagnostics across Australia. The deal also signals growing momentum for 4DMedical’s technology commercialization efforts in both the US and Australian markets.

Notably, 4DMedical’s recent acquisition of Imbio, a pioneer in AI-driven solutions for chronic lung and cardiothoracic diseases, complements this expansion by enhancing diagnostic precision and physician productivity.

Looking Ahead

This agreement with Qscan not only strengthens 4DMedical’s presence in Australia but also sets a precedent for future contracts with other diagnostic imaging providers. As respiratory diseases continue to pose significant healthcare challenges, the demand for advanced imaging solutions is expected to rise, positioning 4DMedical at the forefront of this evolving market.